Related Experiment Videos
Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer
H Saeki1, H Kawaguchi, K Kitamura
1Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan. hsaeki@med.kyushu-u.ac.jp
Background And Objectives:
Hyperthermochemoradiotherapy (HCR) has been performed on numerous patients with esophageal cancer. The purpose of this study is to demonstrate the recent advances in HCR.
Methods:
From 1965 to 1997, 294 patients given preoperative chemoradiotherapy (CR) or HCR were classified according to the anticancer agent that was administered (CR; group A given bleomycin (BLM); group B given cis-diamminedichloroplatinum (II) (CDDP), HCR; group C given BLM; and Group D given CDDP). The local response and the long-term results were investigated.
Results:
The cases in which CR or HCR was evaluated to be effective numbered 44 (48.4%) in group A, 22 (73.3%) in group B, 79 (63.7%) in group C, and 36 (73.5%) in group D. A significant difference was observed between groups A and B (P < 0.05). The highest incidence of markedly effective cases was observed in group D. The 5-year survival rates for the group A and B patients were 17.2% and 43.9%, respectively (P < 0.01), while the same rates for those of groups C and D were 25.6% and 57.8%, respectively (P < 0.05). Our results thus showed CDDP to have a greater effect than BLM, while HCR had a greater effect than CR.
Conclusions:
Preoperative HCR has improved thanks to recent advances in anticancer agents.